<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425580</url>
  </required_header>
  <id_info>
    <org_study_id>EU-nr 2010-022695-31</org_study_id>
    <secondary_id>2010-022695-31</secondary_id>
    <nct_id>NCT01425580</nct_id>
  </id_info>
  <brief_title>Liraglutide and Heart Failure in Type 2 Diabetes</brief_title>
  <official_title>Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Nystrom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with insulinotropic&#xD;
      properties. Apart from the glycemic actions, cardiovascular effects by GLP-1 have recently&#xD;
      been reviewed. Receptors for GLP-1 are expressed in the rodent and human heart and acute&#xD;
      activation of GLP-1 signalling has been shown to influence e.g. heart rate and blood&#xD;
      pressure. In a knock-out mouse model, GLP-1R-/- mice exhibited a defective cardiovascular&#xD;
      contractile response together with left ventricular hypertrophy. GLP-1 improves severe left&#xD;
      ventricular heart failure in humans suffering from a myocardial infarction. Hence, it has&#xD;
      been demonstrated that GLP-1 exerts direct functional effects through both GLP-1 receptor&#xD;
      dependent and independent pathways in the heart.&#xD;
&#xD;
      Native GLP-1 is an extremely short acting peptide, with a half-time breakdown of 1-2 minutes,&#xD;
      a feature that makes it unsuitable as a drug treatment for type 2 diabetes. To this end,&#xD;
      several long-acting GLP-1 analogues, drugs for treating type 2 diabetes, have been tested for&#xD;
      this purpose. The analogue liraglutide exerts its effects via the native GLP-1 receptor,&#xD;
      localized not only on the pancreatic β-cells, but also in the human heart. Interestingly,&#xD;
      liraglutide has been demonstrated to have beneficial effect on heart function in mice. Taken&#xD;
      together, recent data shows that GLP-1 and its stable analogue liraglutide exert beneficial&#xD;
      cardiovascular effects.&#xD;
&#xD;
      The purpose of this study is to determine whether the glucagon-like peptide-1 (GLP-1)&#xD;
      analogue liraglutide improves heart function (measured as left ventricle longitudinal&#xD;
      function and/or functional reserve during rest and/or after exercise) after 18 weeks of&#xD;
      liraglutide + metformin, compared with glimepiride + metformin, using tissue Doppler&#xD;
      echocardiography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects will attend a screening visit (Visit 1) in order to assess their eligibility. If&#xD;
      found eligible, the subjects will return at Visit 2 within approximately 4 weeks, after Visit&#xD;
      1, with an up-titration with metformin 1 g BID or the maximal tolerated dosage of metformin&#xD;
      (Run-in period).&#xD;
&#xD;
      At Visit 2 patients will be tested for;&#xD;
&#xD;
        -  Heart function at rest and during an exercise ECG Stress Test with tissue Doppler&#xD;
           echocardiography&#xD;
&#xD;
        -  24-hour blood pressure&#xD;
&#xD;
        -  Anthropometric assessment&#xD;
&#xD;
        -  Symptoms of dyspnea or fatigue (scoring system, classified as NYHA).&#xD;
&#xD;
        -  Quality of life (SF 36)&#xD;
&#xD;
        -  Blood test (venipuncture)&#xD;
&#xD;
      Subsequently thereafter, subjects will during visit 2 be randomized to receive either&#xD;
      liraglutide 1.8 mg s.c. (initial dose of 0.6 mg with an up-titration of 0.6 mg every week,&#xD;
      final dose 1.8 mg QD) or glimepiride 4 mg p.o (initial dose of 2 mg, with an up-titration of&#xD;
      1 mg every week, final dose 4 mg QD).&#xD;
&#xD;
      At Visit 2, subjects will be supplied with a glucose meter (Abbot Contour) and instruction on&#xD;
      use of the device including regular calibration according to the manufacturer's instruction.&#xD;
      Subjects will be instructed on how to record the results of the self measured plasma glucose&#xD;
      (SMPG) values in the meter. Subjects will then ask to monitor a 7 point profile glucose curve&#xD;
      consecutively in three days before visit 3, at visit 4 and at the end of treatment (visit 5).&#xD;
      SMBG values will be transferred via a computerized system (Diasend®).&#xD;
&#xD;
      Visit 3. Telephone visit. Self-reporting glucose measurements.&#xD;
&#xD;
      Visit 4. Telephone visit. Self-reporting glucose measurements.&#xD;
&#xD;
      At week 18 (Visit 5), subjects will be re-tested for:&#xD;
&#xD;
        -  Heart function at rest and during an exercise ECG Stress Test with tissue Doppler&#xD;
           echocardiography&#xD;
&#xD;
        -  24-hour blood pressure&#xD;
&#xD;
        -  Anthropometric assessment&#xD;
&#xD;
        -  Symptoms of dyspnea or fatigue (scoring system, classified as NYHA).&#xD;
&#xD;
        -  Quality of life (SF 36)&#xD;
&#xD;
        -  Blood test (venipuncture)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour blood pressure</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy delivering from the carotid artery</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in serum over time and symptoms of dyspnea or fatigue as assessed by patient and clinician using established scoring systems</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene and protein expression (Affymetrix/proteomics)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of inflammation i.e. hsCRP, IL-6, TNF-α and PAI-1</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of endothelial activation i.e. E-selectin, VCAM-1, ICAM-1 and plasma levels of nitrate/nitrite</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A1c</measure>
    <time_frame>18 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in terms of hypoglycaemia</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF 36)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise ECG, including working capacity</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global LV function (echocardiography) expressed as ejection fraction (EF)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg p.o. (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>1.8 mg s.c. (QD)</description>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>4 mg p.o. (QD)</description>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg p.o. (BID)</description>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 diabetes.&#xD;
&#xD;
          2. Heart Failure, visualized with echocardiography, one of the following (2.1, 2.2 or&#xD;
             2.3).&#xD;
&#xD;
               -  Ejection Fraction ≤ 50%.&#xD;
&#xD;
               -  Decreased systolic velocity (four chamber view) where two, out of four segments&#xD;
                  (Septum, Lateral, Inferior and Anterior Wall) has a relative decrease in velocity&#xD;
                  of 20% compared to a normal population.&#xD;
&#xD;
               -  Evidence of diastolic dysfunction as shown by abnormal left ventricular&#xD;
                  relaxation, filling, diastolic distensibility or stiffness. An E/E' ratio (ratio&#xD;
                  of early diastolic velocities of mitral inflow derived Doppler imaging and&#xD;
                  myocardial movement derived by tissue Doppler imaging) &gt;15 is considered&#xD;
                  diagnostic of diastolic dysfunction and an E/E' ratio &lt; 8 as diagnostic of the&#xD;
                  absence of diastolic heart failure. An increased left atrial size (&gt;49 ml/ m2)&#xD;
                  and an increased left ventricular mass (&gt;122 g/m2 in women and &gt;149 g/m2 in men)&#xD;
                  are considered sufficient evidence of diastolic dysfunction when the E/E' ratio&#xD;
                  is inconclusive.&#xD;
&#xD;
          3. HbA1c (accordingly to IFCC) 47 mmol/mol - 95 mmol/mol.&#xD;
&#xD;
          4. If antihypertensive treatment, the medication has to be stable, no change, for the&#xD;
             last 1 month.&#xD;
&#xD;
          5. Male and female subjects, 18-80 years of age.&#xD;
&#xD;
          6. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes (autoantibody positive).&#xD;
&#xD;
          2. Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors (DPP-IV&#xD;
             inhibitor) or glimeperide.&#xD;
&#xD;
          3. Previous treatment with glitazones within 6 months.&#xD;
&#xD;
          4. Previous treatment with other sulphonylurea within 3 months.&#xD;
&#xD;
          5. Previous treatment with insulin (any regimen) within 1 month.&#xD;
&#xD;
          6. Known severe heart failure, classified as NYHA 3-4.&#xD;
&#xD;
          7. Significant ischemic heart disease (defined as angina-limited exercise or unstable&#xD;
             angina); documented acute myocardial infarction (MI) within the previous 8 weeks.&#xD;
&#xD;
          8. Active myocarditis; malfunctioning artificial heart valve.&#xD;
&#xD;
          9. Atria fibrillation or flutter&#xD;
&#xD;
         10. History of ventricular tachycardia within 3 months before study entry; second- or&#xD;
             third-degree atrioventricular block.&#xD;
&#xD;
         11. Implanted pacemaker.&#xD;
&#xD;
         12. Supine systolic blood pressure &lt;85 mm Hg or &gt;200 mm Hg.&#xD;
&#xD;
         13. Primary renal impairment (creatinine clearance &lt; 30 ml/min), or creatinine clearance &lt;&#xD;
             60 ml/min if treated with metformin.&#xD;
&#xD;
         14. Uncorrected hypokalemia or hyperkalemia (potassium &lt;3.5 mmol/l or &gt;5.5 mmol/l).&#xD;
&#xD;
         15. Significant anemia (Hb &lt; 90 g/l)&#xD;
&#xD;
         16. Treatment with another investigational agent within 30 days before study entry, judged&#xD;
             by the investigator.&#xD;
&#xD;
         17. Severe gastrointestinal disease, including gastroparesis. As judged by the&#xD;
             investigator.&#xD;
&#xD;
         18. Body mass index (BMI) &gt; 40 kg/m2.&#xD;
&#xD;
         19. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in&#xD;
             the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the&#xD;
             skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to&#xD;
             enter the trial.&#xD;
&#xD;
         20. Females of child bearing potential who are pregnant, breast-feeding or intend to&#xD;
             become pregnant or are not using adequate contraceptive methods (adequate&#xD;
             contraceptive measures as required by local law or practice).&#xD;
&#xD;
         21. Current drug and alcohol abuse.&#xD;
&#xD;
         22. History of acute or chronic pancreatitis&#xD;
&#xD;
         23. Subjects considered by the investigator to be unsuitable for the study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Jendle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Örebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Thomas Nystrom</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Liraglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

